EXS4318

EXS4318 is a selective PKC theta inhibitor that is potentially first-in-class medication. Developed by Exscientia, it was licensed to Bristol Myers Squibb.[

EXS4318

EXS4318 is a selective PKC theta inhibitor that is potentially first-in-class medication. Developed by Exscientia, it was licensed to Bristol Myers Squibb.[1][2] In 2023, it entered clinical trials in humans.[3]

References

  1. ^ Philippidis, Alex (1 January 2023). "BMS Collaboration Paying Off for Exscientia: AI drug developer designs EXS4318, the I&I small molecule that has entered Phase I trials overseen by pharma giant in up-to-$1.3B+ partnership". GEN Edge. 5 (1): 147–150. doi:10.1089/genedge.5.1.31.
  2. ^ Arnold, Carrie (1 June 2023). "Inside the nascent industry of AI-designed drugs". Nature Medicine. 29 (6): 1292–1295. doi:10.1038/s41591-023-02361-0. ISSN 1546-170X. PMID 37264208.
  3. ^ "BMS in-licensed PKC theta inhibitor enters clinical trials". European Pharmaceutical Review. Retrieved 4 November 2023.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.